Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya
12 mars 2024 11h01 HE
|
Intrommune Therapeutics
Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board.
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
22 févr. 2024 09h34 HE
|
Intrommune Therapeutics
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects
Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
06 févr. 2024 09h34 HE
|
Intrommune Therapeutics
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
08 janv. 2024 09h05 HE
|
Intrommune Therapeutics
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
09 nov. 2023 11h01 HE
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy
Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy
25 juil. 2023 09h35 HE
|
Intrommune Therapeutics
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
26 oct. 2022 09h35 HE
|
Intrommune Therapeutics
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...
Intrommune Expands and Strengthens Senior Leadership Team
28 sept. 2022 09h35 HE
|
Intrommune Therapeutics
Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development Appointment of William Berger, MD, MBA as Head of...
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
22 juin 2022 09h31 HE
|
Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Recent Peer-Reviewed Publication Confirms Patient Satisfaction with Multiple Allergy Immunotherapy Options
17 nov. 2021 09h30 HE
|
Allovate, LLC
New York, Nov. 17, 2021 (GLOBE NEWSWIRE) -- A recent article in the peer-reviewed journal International Forum of Allergy and Rhinology reported the results of a survey offered to individuals with...